Literature DB >> 16620998

The changing epidemiology of hospitalized pediatric patients in three measles outbreaks.

Kyung-Yil Lee1, Hyung-Shin Lee, Jae-Kyun Hur, Jin-Han Kang, Byung-Churl Lee.   

Abstract

OBJECTIVES: To assess the demographic and clinical findings of measles patients during three epidemics from 1989 to 2001.
METHODS: A total 520 medical records of measles patients were analyzed retrospectively and divided into three groups; those who were admitted during 1989-1990 (group I, 116 patients), those admitted during 1993-1994 (group II, 127 patients), and those admitted during 2000-2001 (group III, 277 patients).
RESULTS: For the age distribution, there was no difference in the proportion of < 2 years of age (61%, 58% and 57%, respectively) for the three groups. However, in each outbreak, there were significant differences in the distribution of > or = 2 years children who had mostly received one-dose measles-mumps-rubella (MMR) vaccination. The age distribution had changed with a significant increase in older children in subsequent outbreaks. In the last 2000-2001 outbreak, there was a pattern for increased attack rates with increasing interval since the initial vaccination. There was no statistical difference between the three groups in gender ratio, MMR vaccination rate in > or = 2 years of age, duration of fever, and complications. No difference was found in all the clinical and laboratory parameters between the anti-measles IgM antibody negative patients and the positive patients.
CONCLUSIONS: The age distribution of admitted children with measles in each outbreak has changed over time since the introduction of one-dose MMR vaccination. This finding suggests that the secondary vaccine failure may have played a large role in the last measles outbreak.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16620998     DOI: 10.1016/j.jinf.2006.02.016

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  8 in total

1.  Associations between demographic variables and multiple measles-specific innate and cell-mediated immune responses after measles vaccination.

Authors:  Benjamin J Umlauf; Iana H Haralambieva; Inna G Ovsyannikova; Richard B Kennedy; V Shane Pankratz; Robert M Jacobson; Gregory A Poland
Journal:  Viral Immunol       Date:  2012-01-12       Impact factor: 2.257

Review 2.  Vaccines for measles, mumps and rubella in children.

Authors:  Vittorio Demicheli; Alessandro Rivetti; Maria Grazia Debalini; Carlo Di Pietrantonj
Journal:  Cochrane Database Syst Rev       Date:  2012-02-15

Review 3.  Vaccines for measles, mumps, rubella, and varicella in children.

Authors:  Carlo Di Pietrantonj; Alessandro Rivetti; Pasquale Marchione; Maria Grazia Debalini; Vittorio Demicheli
Journal:  Cochrane Database Syst Rev       Date:  2021-11-22

4.  Difference of clinical features in childhood Mycoplasma pneumoniae pneumonia.

Authors:  You-Sook Youn; Kyung-Yil Lee; Ja-Young Hwang; Jung-Woo Rhim; Jin-Han Kang; Joon-Sung Lee; Ji-Chang Kim
Journal:  BMC Pediatr       Date:  2010-07-06       Impact factor: 2.125

5.  Vaccines for measles, mumps, rubella, and varicella in children.

Authors:  Carlo Di Pietrantonj; Alessandro Rivetti; Pasquale Marchione; Maria Grazia Debalini; Vittorio Demicheli
Journal:  Cochrane Database Syst Rev       Date:  2020-04-20

Review 6.  A common immunopathogenesis mechanism for infectious diseases: the protein-homeostasis-system hypothesis.

Authors:  Kyung-Yil Lee
Journal:  Infect Chemother       Date:  2015-03-30

7.  Outbreaks of mumps: an observational study over two decades in a single hospital in Korea.

Authors:  Ji-Ung Ryu; Eun-Kyung Kim; You-Sook Youn; Jung-Woo Rhim; Kyung-Yil Lee
Journal:  Korean J Pediatr       Date:  2014-09-30

8.  Occurrence of measles in a country with elimination status: Amplifying measles infection in hospitalized children due to imported virus.

Authors:  HyeEun Eom; YoungJoon Park; JooWhee Kim; Jeong-Sun Yang; HaeJi Kang; Kisoon Kim; Byung Chul Chun; Ok Park; Jeong Ik Hong
Journal:  PLoS One       Date:  2018-02-15       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.